Merus N.V. (NASDAQ:MRUS) Receives $92.35 Consensus Price Target from Analysts

Merus N.V. (NASDAQ:MRUS) has been assigned an average rating of “Hold” from the eighteen ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $93.5625.

A number of research analysts have weighed in on the stock. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a research note on Monday, August 25th. Needham & Company LLC downgraded shares of Merus from a “buy” rating to a “hold” rating and set a $96.00 price target on the stock. in a report on Monday, September 29th. Leerink Partners reissued a “market perform” rating and issued a $97.00 price objective (up previously from $95.00) on shares of Merus in a research note on Monday, October 6th. Canaccord Genuity Group lowered Merus from a “buy” rating to a “hold” rating and boosted their target price for the company from $67.00 to $97.00 in a research report on Monday, September 29th. Finally, Guggenheim reiterated a “neutral” rating and issued a $97.00 price target (down from $109.00) on shares of Merus in a report on Tuesday, September 30th.

Institutional Trading of Merus

A number of large investors have recently made changes to their positions in MRUS. CWM LLC boosted its position in Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 601 shares during the period. Quarry LP bought a new position in shares of Merus during the 3rd quarter worth $42,000. Farther Finance Advisors LLC increased its stake in shares of Merus by 10,400.0% during the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 520 shares during the period. Longfellow Investment Management Co. LLC bought a new stake in shares of Merus in the third quarter valued at about $75,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Merus by 955.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,624 shares in the last quarter. 96.14% of the stock is owned by hedge funds and other institutional investors.

Merus Price Performance

NASDAQ:MRUS opened at $95.95 on Tuesday. The firm has a market capitalization of $7.28 billion, a price-to-earnings ratio of -18.10 and a beta of 1.26. The business has a 50 day simple moving average of $90.17 and a 200-day simple moving average of $69.61. Merus has a 1 year low of $33.19 and a 1 year high of $96.28.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.